CTRI/2024/06/068239尚未招募2 期
A double-blind, randomized, study on the efficacy of individualized Homoeopathic medicines in treating Hemorrhoids- a placebo controlled trial. - Nil
The Calcutta Homoeopathic Medical College and Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •i) Age 18-65 years
- •ii) First degree (grade I) haemorrhoids without prolapse outside of anal canal
- •iii) Second degree (grade II) haemorrhoids that prolapse with straining, but retract spontaneously
- •iv) With any of the following clinical symptoms: bleeding, pain (including discomfort and tenesmus during defecation or any other time), heaviness, pruritus, and mucus discharge.
- •v) Illiterate people will be interviewed by the investigators maintaining adequate privacy to fill up the scales or questionnaires
- •vi) Literate patients; ability to read Bengali and/or English and/or Hindi
- •vii) Patients giving written consent to participate
排除标准
- •i) Pregnant or lactating women
- •ii) Forth degree (grade IV) haemorrhoids
- •iii) External haemorrhoids
- •iv) Skin tags
- •v) Malignancies
- •vi) Rectal polyps
- •vii) Anal fissure
- •viii) Irritable bowel syndrome
- •ix) Unstable mental or psychiatric illness or other systemic diseases (e.g., uncontrolled hypertension, diabetes, thyroid diseases etc.) affecting quality of life or any vital organ failure.
- •x) Any substance abuses
- •xi) Self-reported immune – compromised state
- •xii) Patients who are too sick for consultation
- •xiii) Simultaneous participation of any other clinical trials.
- •xiv) Undergoing homoeopathic treatment for any chronic disease within last 6 month.
研究者
相似试验
已完成
不适用
A double blind randomized study on the effectiveness of cyclopentolate 1% and cyclopentolate 1% with tropicamide 1% in dark irided hypermetropic childreEye strenght. Refraction10047518NL-OMON30949Medisch Centrum Haaglanden45
进行中（未招募）
1 期
Efficacy and Safety of REGN727 added-on to Rosuvastatin versus Ezetimibe added-on to Rosuvastatin versus Rosuvastatin dose increase in patients who are not controlled on RosuvastatiPatients with Non-familial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH) at high CV risk who are not adequately controlled with rosuvastatin (10mg or 20mg) with or without other lipid-modifying therapy (LMT) (excluding EZE)MedDRA version: 14.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-002333-11-ESRegeneron Pharmaceuticals, Inc.305
进行中（未招募）
不适用
Efficacy and Safety of REGN727/SAR236553 added-on to Atorvastatin versus Ezetimibe added-on to Atorvastatin versus Atorvastatin dose increase versus switch to Rosuvastatin in patients who are not controlled on AtorvastatiEUCTR2012-002344-24-DERegeneron Pharmaceuticals, Inc.420
进行中（未招募）
不适用
Efficacy and Safety of REGN727 added-on to Rosuvastatin versus Ezetimibe added-on to Rosuvastatin versus Rosuvastatin dose increase in patients who are not controlled on RosuvastatiPatients with Non-familial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH) at high CV risk who are not adequately controlled with rosuvastatin (10mg or 20mg) with or without other lipid-modifying therapy (LMT) (excluding EZE)MedDRA version: 16.0Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-002333-11-DERegeneron Pharmaceuticals, Inc.361
进行中（未招募）
1 期
Efficacy and Safety of REGN727/SAR236553 added-on to Atorvastatin versus Ezetimibe added-on to Atorvastatin versus Atorvastatin dose increase versus switch to Rosuvastatin in patients who are not controlled on AtorvastatiEUCTR2012-002344-24-ESRegeneron Pharmaceuticals, Inc.355